Edelweiss Recently Listed IPO Fund vs HDFC Pharma and Healthcare Fund
Direct Plan, Growth option · Data as on 30-10-2026
Edelweiss Recently Listed IPO Fund is a Thematic fund and HDFC Pharma and Healthcare Fund is a Thematic fund. In the 3 years to 30-10-2026, Edelweiss Recently Listed IPO Fund (Direct) returned 16.5% a year and HDFC Pharma and Healthcare Fund (Direct) returned 30.5% a year. Edelweiss Recently Listed IPO Fund charges 1.32% a year and HDFC Pharma and Healthcare Fund 1.05% (Direct plans). Their portfolios overlap 5.4%: they hold 5 of the same securities.
Edelweiss Recently Listed IPO Fund
Thematic
- 3 year return
- 16.5%
- Expense ratio
- 1.32%
- NAV
- ₹34.14
HDFC Pharma and Healthcare Fund
Thematic
- 3 year return
- 30.5%
- Expense ratio
- 1.05%
- NAV
- ₹21.95
Which is better, Edelweiss Recently Listed IPO or HDFC Pharma and Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- HDFC Pharma and Healthcare returned more over 3 years: 30.5% a year against 16.5%.
- HDFC Pharma and Healthcare returned more over 1 year: 23.1% against 14.8%.
- HDFC Pharma and Healthcare costs less: 1.05% a year against 1.32% (Direct plans).
- HDFC Pharma and Healthcare swung less over 3 years: a standard deviation of 14.1% a year against 18.0%.
- HDFC Pharma and Healthcare fell less in its worst fall since 04-10-2023: −14.9% against −24.8%.
- HDFC Pharma and Healthcare holds more in large companies: 29.2% of the fund in large caps against 8.2%.
- HDFC Pharma and Healthcare is the larger fund: ₹3,501 Cr against ₹1,276 Cr.
- Their portfolios overlap 5.4%: 5 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Edelweiss Recently Listed IPO Fund | HDFC Pharma and Healthcare Fund |
|---|---|---|
| Fund house | Edelweiss Mutual Fund | HDFC Mutual Fund |
| Category | Thematic | Thematic |
| AUM | ₹1,276 Cr (30-09-2026) | ₹3,501 Cr (30-09-2026) |
| NAV | ₹34.14 (Direct) | ₹21.95 (Direct) |
| Expense ratio (Direct) | 1.32% | 1.05% |
| Expense ratio (Regular) | 2.58% | 2.13% |
| Riskometer | Very High | Very High |
| Benchmark | Nifty IPO TRI | BSE Healthcare TRI |
| Launch date | 22-02-2018 | 04-10-2023 |
| Minimum investment | ₹100 | ₹100 |
| Lock in | None | None |
| Fund managers | Bharat Lahoti, Bhavesh Jain | Nikhil Mathur, Gopal Agrawal, Bhagyesh Kagalkar |
| Exit load | Exit load of 2% if redeemed within 6 months. | In respect of each purchase/switch-in of units, an Exit load of 1% is payable if units are redeemed /switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched out after 30 days from the date of allotment. |
Edelweiss Recently Listed IPO vs HDFC Pharma and Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Edelweiss Recently Listed IPO Fund (Direct) | −3.79% | +3.64% | +10.59% | +14.82% | +16.50% | +10.65% | -- |
| HDFC Pharma and Healthcare Fund (Direct) | +0.04% | +0.83% | +16.68% | +23.12% | +30.53% | -- | -- |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | -- | -- |
Category average: the average of the 235 Thematic funds, same plan type.
Edelweiss Recently Listed IPO vs HDFC Pharma and Healthcare: Year-wise Returns
| Year | Edelweiss Recently Listed IPOEdelweiss Recently Listed IPO | HDFC Pharma and HealthcareHDFC Pharma and Healthcare |
|---|---|---|
| 2026to date | +17.22% | +23.99% |
| 2025 | −4.38% | +2.42% |
| 2024 | +30.50% | +52.22% |
| 2023 | +36.04% | -- |
| 2022 | −19.29% | -- |
| 2021 | +58.01% | -- |
Edelweiss Recently Listed IPO vs HDFC Pharma and Healthcare: Rolling Returns
Every holding period of both funds, against Nifty IPO TRI, the benchmark of Edelweiss Recently Listed IPO Fund
Rolling returns
Every 1-year holding period, 510 of them, one for each trading day from 04-10-2024 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
Edelweiss Recently Listed IPO Fund (Direct)
HDFC Pharma and Healthcare Fund (Direct)
Nifty IPO TRI
to
Dec 2024Apr 2024
to
Apr 2025Aug 2024
to
Aug 2025Dec 2024
to
Dec 2025May 2025
to
May 2026Aug 2025
to
Aug 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Edelweiss Recently Listed IPO | 12.9 | 25.7 | 14.3 | 8.2 | 13.1 | 13.7 | 12.0 | 11.2% | 8.8% | −8.4% | 34.2% | 100% |
| HDFC Pharma and Healthcare | 0.0 | 4.3 | 15.7 | 9.2 | 10.0 | 17.6 | 43.1 | 24.6% | 22.7% | 1.7% | 67.3% | 98% |
| Nifty IPO TRI | 40.6 | 11.1 | 18.4 | 26.0 | 3.8 | 0.0 | 0.0 | 3.3% | 4.4% | −13.1% | 17.6% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is Nifty IPO TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 04-10-2023. Past returns do not promise future returns.
Edelweiss Recently Listed IPO vs HDFC Pharma and Healthcare: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 03-10-2023 to 30-10-2026: 37 instalments, ₹3,70,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Edelweiss Recently Listed IPOEdelweiss Recently Listed IPO Fund (Direct) | ₹3,70,000 | ₹4,60,927 | ₹90,927 | 14.4% |
| HDFC Pharma and HealthcareHDFC Pharma and Healthcare Fund (Direct) | ₹3,70,000 | ₹5,26,145 | ₹1,56,145 | 23.6% |
Edelweiss Recently Listed IPOEdelweiss Recently Listed IPO Fund (Direct)
HDFC Pharma and HealthcareHDFC Pharma and Healthcare Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Edelweiss Recently Listed IPO vs HDFC Pharma and Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Edelweiss Recently Listed IPO Fund (Direct) | HDFC Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +14.82% | +23.12% |
| Standard deviation | 17.85% | 13.67% |
| Sharpe ratio | 0.54 | 1.31 |
| Sortino ratio | 0.77 | 1.93 |
| Maximum drawdown | −13.7% (31-03-2026) | −9.8% (23-10-2026) |
| Beta | 0.96 | 0.95 |
| Alpha | +10.53% | +11.09% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Edelweiss Recently Listed IPO Fund (Direct) | HDFC Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +16.50% | +30.53% |
| Standard deviation | 17.99% | 14.09% |
| Sharpe ratio | 0.58 | 1.74 |
| Sortino ratio | 0.78 | 2.49 |
| Maximum drawdown | −24.8% (03-03-2025) | −14.9% (28-02-2025) |
| Beta | -- | 0.96 |
| Alpha | -- | +8.23% |
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Edelweiss Recently Listed IPO Fund (Direct) | HDFC Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +15.19% | +29.32% |
| Standard deviation | 18.62% | 13.98% |
| Sharpe ratio | 0.53 | 1.66 |
| Sortino ratio | 0.72 | 2.38 |
| Maximum drawdown | −32.3% (24-03-2020) | −14.9% (28-02-2025) |
| Beta | -- | 0.95 |
| Alpha | -- | +8.51% |
From daily NAVs, 27-02-2018 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Edelweiss Recently Listed IPO Fund (Direct)
HDFC Pharma and Healthcare Fund (Direct)
Nifty IPO TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Edelweiss Recently Listed IPO Fund (Direct) | −24.8% | 03-01-2025 | 03-03-2025 | 04-05-2026 | 14 months | −7.4% |
| HDFC Pharma and Healthcare Fund (Direct) | −14.9% | 02-01-2025 | 28-02-2025 | 04-07-2025 | 4 months | −4.1% |
| Nifty IPO TRI | −28.4% | 23-09-2024 | 07-04-2025 | 20-08-2026 | 16 months | −8.7% |
From daily values since 04-10-2023, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Edelweiss Recently Listed IPO Fund (Direct)
HDFC Pharma and Healthcare Fund (Direct)
Nifty IPO TRI
Against Nifty IPO TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| Edelweiss Recently Listed IPO Fund (Direct) | 110% | 82% | 5.93% |
| HDFC Pharma and Healthcare Fund (Direct) | 77% | 14% | 17.06% |
From month-end values since 04-10-2023. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
Edelweiss Recently Listed IPO vs HDFC Pharma and Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: Edelweiss Recently Listed IPO Fund, September 2026; HDFC Pharma and Healthcare Fund, September 2026
Holdings in common
- Overlap
- 5.4%
- Held by both
- 5
- Only in Edelweiss Recently Listed IPO
- 49
- Only in HDFC Pharma and Healthcare
- 33
| Security | % of Edelweiss Recently Listed IPO | % of HDFC Pharma and Healthcare |
|---|---|---|
| Molbio Diagnostics Ltd. | 1.95% | 2.01% |
| Corona Remedies Ltd. | 2.21% | 1.04% |
| Sai Life Sciences Ltd | 0.96% | 1.58% |
| Rubicon Research Ltd. | 0.89% | 2.52% |
| Symbiotec Pharmalab Ltd. | 0.53% | 1.36% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 5.4% means 5.4% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Edelweiss Recently Listed IPO Fund
| Security | % of fund |
|---|---|
| ICICI Prudential Asset Mgmt Co Ltd. | 5.78% |
| NSE India Ltd. | 5.32% |
| Meesho Ltd. | 5.12% |
| Shadowfax Technologies Ltd. | 4.00% |
| Sedemac Mechatronics Ltd. | 3.97% |
Largest holdings only in HDFC Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Divis Laboratories Ltd. | 9.39% |
| Sun Pharmaceutical Industries Ltd. | 8.28% |
| Alkem Laboratories Ltd. | 4.64% |
| Cipla Ltd. | 4.15% |
| Apollo Hospitals Enterprise Ltd. | 3.69% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Edelweiss Recently Listed IPO | HDFC Pharma and Healthcare |
|---|---|---|
| Equity | 97.0% | 96.8% |
| Debt | 0.2% | 0.0% |
| Cash and others | 2.8% | 3.2% |
Market cap of stocks
| Market cap | Edelweiss Recently Listed IPO | HDFC Pharma and Healthcare |
|---|---|---|
| Large Cap | 8.2% | 29.2% |
| Mid Cap | 7.6% | 30.1% |
| Small Cap | 42.8% | 32.5% |
| Not on AMFI's list | 38.5% | 5.0% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Edelweiss Recently Listed IPO | HDFC Pharma and Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 4.6% | 71.3% |
| Healthcare Services | 1.1% | 22.1% |
| Capital Markets | 16.1% | 0.0% |
| Retailing | 10.6% | 1.0% |
| Auto Components | 9.4% | 0.0% |
| Electrical Equipment | 7.3% | 0.0% |
| Chemicals & Petrochemicals | 6.1% | 0.0% |
| Industrial Manufacturing | 6.0% | 0.0% |
| Healthcare Equipment & Supplies | 1.9% | 2.4% |
The six largest sectors of each fund's stocks, % of the fund.
Edelweiss Recently Listed IPO vs HDFC Pharma and Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Edelweiss Recently Listed IPO Fund | HDFC Pharma and Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | 1.32% | 1.05% |
| Base expense ratio (Direct) | 0.80% | 0.71% |
| Total expense ratio (Regular) | 2.58% | 2.13% |
| Base expense ratio (Regular) | 1.87% | 1.65% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Edelweiss Recently Listed IPO with
Edelweiss Recently Listed IPO Fund vs HDFC Pharma and Healthcare Fund: Frequently Asked Questions
What is the difference between Edelweiss Recently Listed IPO Fund and HDFC Pharma and Healthcare Fund?
Edelweiss Recently Listed IPO Fund is a Thematic fund, HDFC Pharma and Healthcare Fund is a Thematic fund, run by Edelweiss Mutual Fund and HDFC Mutual Fund. Their portfolios overlap 5.4%. Edelweiss Recently Listed IPO Fund charges 1.32% a year and HDFC Pharma and Healthcare Fund 1.05%.
Which has given higher returns, Edelweiss Recently Listed IPO Fund or HDFC Pharma and Healthcare Fund?
Over 1 year: Edelweiss Recently Listed IPO Fund +14.82%, HDFC Pharma and Healthcare Fund +23.12%. Over 3 years: Edelweiss Recently Listed IPO Fund +16.50% a year, HDFC Pharma and Healthcare Fund +30.53% a year. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, Edelweiss Recently Listed IPO Fund or HDFC Pharma and Healthcare Fund?
HDFC Pharma and Healthcare Fund charges less: 1.05% a year against 1.32%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Edelweiss Recently Listed IPO Fund and HDFC Pharma and Healthcare Fund overlap?
5.4%. They hold 5 of the same securities, the largest shared ones being MOLBIO, CORONA, SAILIFE. From each fund's latest monthly portfolio.
Which is riskier, Edelweiss Recently Listed IPO Fund or HDFC Pharma and Healthcare Fund?
On SEBI's riskometer, Edelweiss Recently Listed IPO Fund is rated Very High and HDFC Pharma and Healthcare Fund Very High. Over 3 years, the standard deviation of daily returns was 17.99% and 14.09% a year.
Which is better for SIP, Edelweiss Recently Listed IPO Fund or HDFC Pharma and Healthcare Fund?
Over the last 3 years, a monthly SIP of ₹10,000 from 03-10-2023 to 30-10-2026 grew to ₹4,60,927 in Edelweiss Recently Listed IPO Fund (XIRR 14.4% a year) and ₹5,26,145 in HDFC Pharma and Healthcare Fund (XIRR 23.6% a year). Both received 37 instalments. Past returns do not promise future returns.
Can I invest in both Edelweiss Recently Listed IPO Fund and HDFC Pharma and Healthcare Fund?
Yes. 5.4% of each fund's money sits in the same holdings, so the two hold mostly different investments.
Who manages Edelweiss Recently Listed IPO Fund and HDFC Pharma and Healthcare Fund?
Edelweiss Recently Listed IPO Fund: Bharat Lahoti, Bhavesh Jain. HDFC Pharma and Healthcare Fund: Nikhil Mathur, Gopal Agrawal, Bhagyesh Kagalkar.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.